INHIBRX BIOSCIENCES, INC. Payment for Debt Extinguishment or Debt Prepayment Cost
INHIBRX BIOSCIENCES, INC. (INBX) had Payment for Debt Extinguishment or Debt Prepayment Cost of $18.00 million as of 2024-05-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2025-11-14
- 2024-05-30: Payment for Debt Extinguishment or Debt Prepayment Cost $18.00M.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost |
|---|---|
| 2024-05-30 | $18.00M 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |